Xenon Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery and development of innovative therapeutics for neurological disorders and other serious conditions
Utilizing its proprietary gene modulation platform, the company aims to identify and advance novel drug candidates that target the underlying causes of diseases rather than merely addressing symptoms. By leveraging its expertise in genetic insights and biochemical pathways, Xenon strives to improve patient outcomes through precision medicine, building a robust pipeline of potential treatments for conditions such as epilepsy and other central nervous system disorders.
Xenon Pharmaceuticals Inc (NASDAQXENE) shares are trading higher by 7.8% to $36.38 Thursday afternoon. The company announced the pricing of its upsized $300 million public offering of 8,461,542 common shares at
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Monday, Xenon Pharmaceuticals Inc (NASDAQXENE) reported topline results from the Phase 2 proof-of-concept X-NOVA trial, which evaluated the clinical efficacy, safety, and tolerability of 10 mg and 20 mg of XEN1101 in 168 patients with moderate to severe
Biohaven's potential with RBC Capital Markets' optimistic outlook.. RBC sees blockbuster potential of $3.2 billion across epilepsy and mood disorders. Anticipate significant developments in lead asset Kv7-7000's Phase 3 trial this year, reducing late-stage risks.
Xenon Pharmaceuticals Inc (NASDAQXENE) reported topline results from the Phase 2 proof-of-concept X-NOVA trial, which evaluated the clinical efficacy, safety, and tolerability of 10 mg and 20 mg of XEN1101 in 168 patients with moderate to severe
U.S. stocks traded mostly lower, with the Dow Jones falling around 50 points on Monday. Shares of Ituran Location and Control Ltd. (NASDAQITRN) gained during Monday’s session after the company reported third-quarter financial results.
Companies Reporting Before The Bell • Kosmos Energy (NYSEKOS) is expected to report quarterly earnings at $0.17 per share on revenue of $440.16 million.
